BD Q2 Beats, ASR Executed, Guidance Raised – FDA Overhang Persists

What happened

BD reported Q2 FY2026 revenue of $4.7B (+5.2% reported, +2.6% FXN), with adjusted EPS of $2.90 beating the prior consensus, though GAAP EPS was -$0.13 due to separation-related charges. The company executed a $2.0B accelerated share repurchase (ASR) and retired $2.1B of debt in the quarter, meeting key capital deployment milestones. Management reaffirmed full-year revenue growth guidance and raised adjusted diluted EPS guidance, signaling confidence in underlying operations despite the Waters spin-off complexity. However, the infusion FDA review remains in 'ongoing' status with no de-escalation, and the January 2026 OAI classification still hangs over the Connected Care segment. The quarter demonstrates that BD can deliver per-share earnings progression through buybacks, but regulatory progress on Alaris remediation remains the critical variable for sustained multiple expansion.

Implication

Capital deployment proof points are now in hand, lowering the probability of the bear case from failed execution. However, infusion regulatory risk persists and could escalate, limiting long-term conviction. Investors should maintain position size and await FDA de-escalation or evidence of Alaris remediation completion before considering a full overweight.

Thesis delta

The core thesis shifts from 'wait for ASR execution' to 'wait for FDA de-escalation,' as the capital deployment risk is now largely retired. The Q2 report validates that BD can meet per-share targets through buybacks, but without regulatory progress, the stock remains range-bound between $140 and $175. The raised guidance is a positive signal, but it does not remove the structural drag from infusion scrutiny.